ReWalk Robotics Reports Third Quarter 2016 Financial Results -- Revenue of $1.4 million -- -- Placed 23 Personal units with 13 positive insurance decisions -- YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA

ReWalk Robotics Reports Third Quarter

2016 Financial Results

-- Revenue of $1.4 million --

-- Placed 23 Personal units with 13 positive

insurance decisions --

YOKNEAM ILIT, ISRAEL / MARLBOROUGH, MA, November 3, 2016

- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk" or "the Company") today announced its financial

results for the three- and nine-month periods ended September 30, 2016.

Highlights of and subsequent to the third quarter include:

"We continue to focus on executing

our strategic plan to build the exoskeleton market. Our efforts with insurance providers have resulted in 64 positive reimbursement

decisions, including 41 so far this year, and we ended the quarter with a strong pipeline of 149 pending insurance claims,"

stated Larry Jasinski, Chief Executive Officer.

"During the first nine months

of 2016, 11 systems were provided to veterans through the Department of Veteran Affairs (VA) Coverage Policy (SOP) and 22 systems

for the VA's ongoing studies regarding the potential benefits of walking in the ReWalk. We expanded the clinical study initiated

with Stanford University to focus more broadly on quality of life, utilization and cost utility outcomes. And, we made meaningful

progress on our research and development efforts on a soft exo-suit technology for stroke and multiple sclerosis patients through

our partnership with the Wyss Institute at Harvard University," he added.

"With our latest financing in

place, we believe we are well-positioned to continue building upon the positive trajectory of our insurance coverage and R&D

efforts, which will enable us to deliver on our milestones," concluded Jasinski.

Third Quarter 2016 Financial

Total revenue was $1.4 million for

the third quarter of 2016, an increase of 20%, compared with $1.2 million in the third quarter of 2015. 23 ReWalk systems were

placed during the third quarter and 80 were placed in the nine months ended September 30, 2016, compared with 23 and 48 ReWalk

systems placed in the corresponding prior year periods. The increase in revenue was driven by unit sales and the conversion of

prior period rentals.

R&D expense was $2.0 million for

the third quarter of 2016, compared to $1.3 million during the same period last year, reflecting investment in product development

ReWalk Robotics Reports Third Quarter 2016 Financial Results

SG&A expense grew to $5.7 million

for the third quarter of 2016, compared to $5.1 million in the prior year period, primarily reflecting investment in reimbursement

Net loss was $7.9 million for the third

quarter of 2016 compared with a net loss of $6.4 million in the prior year quarter. Non-GAAP net loss for the third quarter was

$6.7 million compared with a non-GAAP net loss of $5.8 million in the third quarter of 2015.

A reconciliation of net loss to non-GAAP

net loss is included at the end of this press release under our Condensed Consolidated Statement of Operations.

As of September 30, 2016, ReWalk had

$12.4 million in cash. Subsequent to the end of the quarter, ReWalk raised gross proceeds of $12.2 million in a public offering

of ordinary shares and warrants.

Management is reiterating revenue guidance

in the range of $6.2 to $7.0 million for the full year, subject to the timing of certain key business catalysts including placements

in our international markets, timing of reimbursement decisions, rental unit conversions and larger orders to support the VA's

ReWalk management will host its third

quarter conference call as follows:

A replay of the conference call will

be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International). The

conference ID for the replay is 7986124. The archived webcast will be available for 30 days via the aforementioned URL.

About ReWalk Robotics Ltd.

ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for individuals with spinal cord injury.

Our mission is to fundamentally change the quality of life for individuals with lower limb disability through the creation and

development of market leading robotic technologies. Founded in 2001, ReWalk has headquarters in the U.S., Israel and Germany.

For more information on the ReWalk systems, please visit http://www.rewalk.com.

ReWalk is a registered trademark

of ReWalk Robotics Ltd. in Israel.

ReWalk Robotics Reports Third Quarter 2016 Financial Results

Forward-Looking Statements

addition to historical information, this press release contains forward-looking statements within the meaning of the U.S. Private

Securities Litigation Reform Act of 1995, Section 27A of the U.S. Securities Act of 1933, and Section 21E of the U.S. Securities

Exchange Act of 1934. Such forward-looking statements may include projections regarding ReWalk's future performance and,

in some cases, may be identified by words like "anticipate," "assume," "believe," "continue,"

"could," "estimate," "expect," "intend," "may," "plan,"

"potential," "predict," "project," "future," "will," "should,"

"would," "seek" and similar terms or phrases. The forward-looking statements contained in this press release

are based on management's current expectations, which are subject to uncertainty, risks and changes in circumstances that

are difficult to predict and many of which are outside of ReWalk's control. Important factors that could cause ReWalk's

actual results to differ materially from those indicated in the forward-looking statements include, among others: ReWalk's

expectations regarding future growth, including its ability to increase sales in its existing geographic markets and to expand

to new markets; ReWalk's ability to maintain and grow its reputation and to achieve and maintain market acceptance of its

products; ReWalk's ability to achieve reimbursement from third-party payors for its products; ReWalk's expectations

as to its clinical research program and clinical results; ReWalk's

expectations as to the results of, and the Food and Drug Administration's

potential regulatory actions with respect to, ReWalk's mandatory

post-market 522 surveillance study; the outcome of ongoing shareholder class action litigation relating to ReWalk's

initial public offering; ReWalk's ability to repay its secured indebtedness; ReWalk's ability to improve its products

and develop new products; ReWalk's ability to maintain adequate protection of its intellectual property and to avoid violation

of the intellectual property rights of others; ReWalk's ability to gain and maintain regulatory approvals; ReWalk's

ability to secure capital from its at-the-market equity distribution program based on the price range of its ordinary shares and

conditions in the financial markets; ReWalk's ability to

use effectively the proceeds of its follow-on offering; ReWalk's ability to maintain relationships with existing customers

and develop relationships with new customers; and other factors discussed under the heading "Risk Factors" in ReWalk's

Annual Report on Form 10-K for the year ended December 31, 2015 filed with the U.S. Securities and Exchange Commission and other

documents subsequently filed with or furnished to the U.S. Securities and Exchange Commission. Any forward-looking statement made

in this press release speaks only as of the date hereof. Factors or events that could cause ReWalk's actual results to differ

from the statements contained herein may emerge from time to time, and it is not possible for ReWalk to predict all of them. Except

as required by law, ReWalk undertakes no obligation to publicly update any forward-looking statements, whether as a result of new

information, future developments or otherwise.

Non-GAAP Financial Measures

To supplement its consolidated financial statements, which are

prepared and presented in accordance with U.S. Generally Accepted Accounting Principles (GAAP), ReWalk believes that the use of

non-GAAP accounting measures, including non-GAAP net loss, is helpful to its investors. These measures, which the Company refers

to as non-GAAP financial measures, are not prepared in accordance with GAAP.

For the three and nine months ended September 30, 2016 and 2015,

non-GAAP net loss is calculated as GAAP net loss excluding (i) non-cash share-based compensation expense, (ii) depreciation

and (iii) non-cash financial expenses.

of varying available valuation methodologies, subjective assumptions, and the variety of equity instruments that can impact a company's

non-cash expenses, ReWalk believes that providing non-GAAP financial measures that exclude non-cash share-based compensation expense,

depreciation and non-cash financial (income) expenses allows for more meaningful comparisons between operating results from period